Decreased glycolytic metabolism in non-compaction cardiomyopathy by F-18-fluoro-2-deoxyglucose positron emission tomography: new insights into pathophysiological mechanisms and clinical implications

Imagem de Miniatura
Arquivos
art_MELO_Decreased_glycolytic_metabolism_in_noncompaction_cardiomyopathy_by_F18fluoro2deoxyglucose_2017.PDF (408.08 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS
Autores
BIERRENBACH, Ana Luiza de Souza
Citação
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, v.18, n.8, p.915-921, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Aims The pathophysiological mechanisms of left ventricular non-compaction cardiomyopathy (LVNC) remain controversial. This study performed combined F-18-fluoro-2-deoxyglucose dynamic positron emission tomography (FDG-PET) and 99mTc-sestamibi single-photon emission computed tomography (SPECT) studies to evaluate myocardial glucose metabolism and perfusion in patients with LVNC and their clinical implications. Methods and results Thirty patients (41 +/- 12 years, 53% male) with LVNC, diagnosed by cardiovascular magnetic resonance (CMR) criteria, and eight age-matched healthy controls (42 +/- 12 years, 50% male) were prospectively recruited to undergo FDG-PET with measurement of the myocardial glucose uptake rate (MGU) and SPECT to investigate perfusion-metabolism patterns. Patients with LVNC had lower global MGU compared with that in controls (36.9 +/- 8.8 vs. 44.6 +/- 5.4 mu mol/min/100 g, respectively, P = 0.02). Of 17 LV segments, MGU levels were significantly reduced in 8, and also a reduction was observed when compacted segments from LVNC were compared with the segments from control subjects (P < 0.001). Perfusion defects were also found in 15 (50%) patients (45 LV segments: 64.4% match, and 35.6% mismatch perfusion-metabolism pattern). Univariate and multivariate analyses showed that beta-blocker therapy was associated with increased MGU (beta coefficient = 10.1, P = 0.008). Moreover, a gradual increase occurred in MGU across the beta-blocker dose groups (P for trend = 0.01). Conclusion The reduction of MGU documented by FDG-PET in LVNC supports the hypothesis that a cellular metabolic pathway may play a role in the pathophysiology of LVNC. The beneficial effect of beta-blocker mediating myocardial.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/21965
Referências
  1. Abdurrachim D, 2015, CARDIOVASC RES, V106, P194, DOI 10.1093/cvr/cvv105
  2. Abozguia K, 2006, NAT CLIN PRACT CARD, V3, P490, DOI 10.1038/ncpcardio0583
  3. Ashrith G, 2014, J CARDIOVASC MAGN R, V16, DOI 10.1186/s12968-014-0064-2
  4. Davila-Roman VG, 2002, J AM COLL CARDIOL, V40, P271, DOI 10.1016/S0735-1097(02)01967-8
  5. Gao XJ, 2014, J NUCL CARDIOL, V21, P633, DOI 10.1007/s12350-014-9890-8
  6. GONG G, 2015, SCIENCE NEW YORK NY, V0350
  7. Lindenfeld J, 2010, J CARD FAIL, V16, P1, DOI 10.1016/J.CARDFAIL.2010.04.004
  8. Hoedemaekers YM, 2010, CIRC-CARDIOVASC GENE, V3, P232, DOI 10.1161/CIRCGENETICS.109.903898
  9. Jenni R, 2002, J AM COLL CARDIOL, V39, P450, DOI 10.1016/S0735-1097(01)01765-X
  10. Kates AM, 2003, J AM COLL CARDIOL, V41, P293, DOI 10.1016/S0735-1097(02)02714-6
  11. Li J, 2015, CLIN RES CARDIOL, V104, P241, DOI 10.1007/s00392-014-0778-z
  12. Lindroos MM, 2016, J INHERIT METAB DIS, V39, P67, DOI 10.1007/s10545-015-9865-1
  13. Liu SH, 2013, MOL GENET METAB, V109, P100, DOI 10.1016/j.ymgme.2013.02.004
  14. Lopaschuk GD, 2007, CIRC RES, V101, P335, DOI 10.1161/CIRCRESAHA.107.150417
  15. Neubauer S, 2007, NEW ENGL J MED, V356, P1140, DOI 10.1056/NEJMra063052
  16. Nickel A, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0358-9
  17. Niemann M, 2012, EUR J HEART FAIL, V14, P155, DOI 10.1093/eurjhf/hfr164
  18. Ortiz-Perez JT, 2008, JACC-CARDIOVASC IMAG, V1, P282, DOI 10.1016/j.jcmg.2008.01.014
  19. Paterick TE, 2012, J AM SOC ECHOCARDIOG, V25, P363, DOI 10.1016/j.echo.2011.12.023
  20. Petersen SE, 2005, J AM COLL CARDIOL, V46, P101, DOI 10.1016/j.jacc.2005.03.045
  21. Ponikowski P, 2016, EUR J HEART FAIL, V18, P891, DOI 10.1002/ejhf.592
  22. RANDLE PJ, 1963, LANCET, V1, P785
  23. Sabbah HN, 2004, HEART FAIL REV, V9, P91, DOI 10.1023/B:HREV.0000046363.59374.23
  24. Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
  25. Soares J, 2014, INT J CARDIOVAS IMAG, V30, P415, DOI 10.1007/s10554-013-0324-5
  26. Taegtmeyer H, 2016, CIRC RES, V118, P1659, DOI 10.1161/RES.0000000000000097
  27. Tang S, 2010, MITOCHONDRION, V10, P350, DOI 10.1016/j.mito.2010.02.003
  28. Towbin JA, 2015, LANCET, V386, P813, DOI 10.1016/S0140-6736(14)61282-4
  29. van den Heuvel AFM, 2000, J AM COLL CARDIOL, V35, P19, DOI 10.1016/S0735-1097(99)00499-4
  30. Wai T, 2015, SCIENCE, V350, DOI 10.1126/science.aad0116
  31. Yamada AT, 2007, ARQ BRAS CARDIOL, V88, P285, DOI 10.1590/S0066-782X2007000300006
  32. Yamano M, 2009, HEART, V95, P1051, DOI 10.1136/hrt.2008.158980

Coleções
Artigos e Materiais de Revistas Científicas - FM/MOG
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - LIM/58
Carregar mais